The Pancreatic Cancer Action Network's (PanCAN) National Board of Directors is comprised of dedicated individuals who are leaders professionally and in their communities with a broad range of expertise including business, higher education, fundraising, policy, legal issues, finances and board governance. Each member has been personally touched by pancreatic cancer and is committed to working with PanCAN to accelerate progress.

Hilarie Koplow-McAdams

Chair, San Francisco, CA

Hilarie Koplow-McAdams joined the technology team of New Enterprise Associates (NEA) as a Venture Partner in 2017, where she focuses on enterprise software and services. She also serves as an independent board director across several public companies.

An enterprise software veteran, Koplow-McAdams spent the last three decades at growth-stage technology companies in operations and board roles. Most recently, she was President at New Relic, responsible for the company's growth strategies as well as leading global sales, marketing, customer success, support and business development. Prior to New Relic, Koplow-McAdams was at Salesforce, who named her President to lead the company's worldwide sales teams, focused on growing the business globally. Koplow-McAdams joined Salesforce from Intuit, where she was Vice President of Direct Sales for small business and a member of the executive committee.

Koplow-McAdams started her career at Oracle Corporation. She held a variety of roles over the course of 18 years at the company, including Senior Vice President of Oracle Direct, where she drove the company's rapid growth in the technology and applications markets.

Koplow-McAdams currently serves as a member of the board of directors for Tableau and Zendesk as well as Chair of the Pancreatic Cancer Action Network. She is also a member on the advisory council of the University of Chicago's Harris School of Public Policy. She previously served on the board of directors for Informatica, now a private company.

Koplow-McAdams has a master's degree in Public Policy from the University of Chicago and a bachelor's degree from Mills College. She lives in the San Francisco Bay Area with her husband Steve and their two daughters.

Karen Young, CPA

Vice Chair, New Jersey

Karen Young, CPA, joined the Pancreatic Cancer Action Network (PanCAN) Board of Directors in May 2018. Young brings 23 years of professional and strategic development expertise to the distinguished role.

Young became impassioned to assist in finding a cure for pancreatic cancer after losing both her father and her aunt to the disease.

Currently, Young works as PricewaterhouseCoopers' (PwC) U.S. Pharmaceutical and Life Sciences Leader (PLS). In this role, she leads more than 3,000 professionals in delivering PwC's advisory, tax and assurance services. She drives the strategic direction in client service, capabilities and thought leadership. Young has deep relationships within the marketplace and has a proven track record in delivering the highest service, leveraging the expertise within the geographies, industry and across all PwC's lines of service.

Outside of the PwC office, Young has received several accolades, including NJBIZ's Best 50 Women in Business Award and the Healthcare Businesswomen's Association's (HBA) Rising Star Award. Additionally, Young is active as a presenter and moderator at several life sciences forums, including CBI Accounting and Reporting Congress and BioNJ. She has authored multiple publications, articles and alerts on accounting and technical matters impacting the industry and broader industry topics, such as the future of healthcare.

Young is a graduate of Villanova University. She lives in New Jersey with her husband Bill and three children: Andrew, Brian and Mary.

Peter Cashion

Washington, D.C.

Peter Cashion is a Chief Investment Officer at the International Finance Corporation (IFC), a member of the World Bank Group, in Washington, D.C. Cashion and his two teenage sons lost wife and mother Andra Tamburro to pancreatic cancer in 2013.

Cashion began his career at IFC in 1995. He has held a variety of senior positions in the Washington, D.C. office and in the field, including postings in Cote d'Ivoire, Senegal, and Turkey. Since relocating from Istanbul to D.C. in 2012, he's been active in promoting women's entrepreneurship and overseeing the equity investment business in financial institutions.

Cashion was IFC's representative on the Steering Committee of the IFC-Goldman Sachs Foundation Women Entrepreneurs Opportunity Facility, a $600 million financing facility for women entrepreneurs in emerging markets. Currently, he is the equity head of the Financial Institutions Group at IFC. Cashion has a regional focus on sub-Saharan Africa and Latin America and oversees an equity portfolio of $2 billion.

Previously, he served in the IFC Treasury for eight years, during which time he was the IFC board member nominee to Titularizadora Colombian (Colombia), the largest mortgage securitization company in Colombia.

Since his wife's passing, Cashion and his boys have been committed, passionate fundraisers for the Pancreatic Cancer Action Network through PurpleStride Washington, D.C. They raised over $180,000 from 2013-2017.

Dennis Cronin

Pittsburgh, PA

Dennis Cronin is a 10-year pancreatic cancer survivor. He is currently Senior Vice President Treasury Service and Chief Risk Officer at Highmark Health, a Pittsburgh-based national health and wellness organization and the second largest integrated delivery and financing system in America. In this role, he is responsible for the oversight of more than $13 billion of investments. In addition, Cronin oversees the Highmark Health capital allocation, risk management and disaster recovery functions.

Prior to his current role, Cronin served as Vice President of Financial Investigations for Highmark Inc., overseeing all aspects of the organization’s fraud and financial recovery activities. Additionally, Cronin was Chief Financial Officer of the HM Insurance Group of companies (HMIG), the consistent presenting sponsor for the Pancreatic Cancer Action Network’s PurpleStride Pittsburgh. Earlier in his career, he worked in various auditing roles, including Highmark internal audit and as an external auditor at KMPG Peat Marwick.

Cronin served on the Pancreatic Cancer Action Network Survivor Council for the past four years and is a board member for the Caring Foundation for Grieving Children. He has previously been a board member of the South Fayette Township Library, served on the Duquesne University Accounting Advisory Committee and participated in the Leadership Pittsburgh program.

Cronin is a graduate of Duquesne University. He lives in Pittsburgh with his wife, Kathy, the Affiliate Chair for the Pittsburgh Affiliate of the Pancreatic Cancer Action Network. They have two adult children – Tyler, who lives in Chicago, and Nikki, who attends Elon University. Together the family has raised more than $350,000 for the Pancreatic Cancer Action Network over the past nine years through their PurpleStride team, Faith Heals, and support generated from Highmark and affiliated companies.

Julie M. Fleshman, JD, MBA

President and CEO, Los Angeles

The Pancreatic Cancer Action Network is a nonprofit, 501(c)(3) nationwide network of people dedicated to fighting the world's toughest cancer. Founded by a group of pancreatic cancer survivors and caregivers in 1999, the organization relentlessly pursues its mission by implementing an aggressive and comprehensive strategy of research, patient support, advocacy and awareness. The Pancreatic Cancer Action Network is headquartered in Manhattan Beach, Calif., and also staffs a Washington, D.C and New York City office.

Julie Fleshman became the organization's first full-time staff person and its first Executive Director in April 2000. Having lost her father to pancreatic cancer in 1999, she has made it her passion and commitment to change the course of the disease. In July 2004, the Board of Directors appointed Fleshman President and CEO. Under her leadership, the Pancreatic Cancer Action Network has grown from a staff of one with revenues of $228,000 to a staff of over 150 with a budget of more than $40 million.

Today, Fleshman is a sought-after speaker with considerable experience addressing diverse stakeholder groups, including Congress, industry, patients, scientists, donors and volunteers. She has also been interviewed by national media such as The New York Times, CNN, Headline News and ABC News as well as local press throughout the country.

Fleshman's leadership has driven consistent excellence and innovation throughout the programs and services of the organization, including introducing precision medicine service Know Your Tumor® and Precision PromiseSM, the first response-adaptive randomized clinical trial for pancreatic cancer. At the same time, she has steadily increased revenue growth and the organization's impact. Under her direction, the organization has greatly expanded and attracted leading researchers from prestigious institutions around the country to study pancreatic cancer.

During Fleshman's tenure, advocacy and grassroots efforts have expanded to over 60 affiliates nationwide and yielded a $160 million increase in federal funding for pancreatic cancer research. The organization has awarded 199 pancreatic cancer research grants and has a projected total research investment of approximately $126 million, including the competitive Research Grants Program and leading-edge scientific and clinical initiatives. Patients, caregivers and healthcare professionals have called upon the organization more than 204,000 times for disease information, treatment options and hope.

Fleshman holds her JD and MBA degrees from Santa Clara University and a BA from the University of California, Santa Barbara, where she graduated Magna Cum Laude. She also studied abroad at Oxford University and in Tokyo, Japan. Fleshman has been honored for her leadership and dedication in the fight against pancreatic cancer by many organizations. She serves on the boards of several cancer care and research committees and organizations, recently completing her term as a patient advocate on the National Cancer Institute's Pancreas Task Force, and she has been published in multiple research journals. Most recently, she was asked to join the FasterCures Patients Count Leadership Council and to serve on the NCI Council of Research Advocates to provide advice to the NCI Director with respect to promoting research outcomes that are in the best interest of cancer patients. In addition, Fleshman is the Chair of the World Pancreatic Cancer Coalition, a coalition of more than 80 pancreatic cancer organizations representing 32 countries around the globe.

Scott A. Griswold, CPA

Los Angeles, CA

Scott A. Griswold, CPA, spent the bulk of his professional life working for David Murdock, owner of Dole Food Company and self-made billionaire. Throughout his career, Griswold provided investment and financial analysis, along with operational oversight.

While Griswold retired as executive vice president (EVP) of corporate development at Dole in 2013, he continued to work at Castle and Cooke Inc., a private holding company for various enterprises owned by Murdock as their EVP of Operations. He made his retirement official in 2014. Currently he spends his free time pursuing leisure activities like golf, and by donating his time and skills to various not-for-profit organizations.

Griswold graduated from Iowa's Luther College with a bachelor of arts degree in accounting. After graduating, he moved to Los Angeles, where he began his professional career within the audit division of Arthur Anderson & Co. He left Arthur Anderson & Co. a decade later as a senior audit manager.

Griswold also serves as a member of the Buck Institute for Research on Aging Impact Circle, an organization responsible for selecting and providing seed money for scientists to do initial testing of their hypothesis. The first two projects received initial funding from the National Institutes of Health (NIH). Griswold is also a member of the board of directors of Ride On, an organization dedicated to enhancing the quality of life of children and adults with disabilities through adaptive horseback riding and therapy services. He is involved with his community Calvary Church. Formerly, Griswold served as a member of the board of directors of the Hollywood YMCA and as a member of the Los Angeles World Affairs Council.

Griswold became passionate about pancreatic cancer awareness, advocacy, fundraising and research after he lost a dear family friend to the disease in 2015.

Griswold lived in Manhattan Beach, CA, for more than 40 years until moving to Pacific Palisades, CA, in 2018. His late wife, Pamela, died of lung cancer in 2016. Griswold has two adult children, James, who lives with his dad in Pacific Palisades, and Tracey, who lives with her husband and daughter in Gilbert, AZ.

Barbara J. Kenner, PhD

New York, NY

Barbara Kenner, PhD, established the Kenner Family Research Fund (KFRF) in 2013 in memory of her husband, Peter, who died in 2010 just two months after he was diagnosed with neuroendocrine pancreatic cancer. The mission of KFRF is to further advance early detection of pancreatic cancer by actively promoting inter-professional strategic collaboration among researchers, government, industry and patient advocacy groups. The Kenner Family Research Fund provides a platform to share the varied expertise and diverse perspectives that challenge current thinking. Published articles resulting from these collaborative forums provide a broader reach of information to the pancreatic cancer community.

Kenner serves as an advocate to the National Cancer Institute's Alliance of Pancreatic Cancer Detection Consortium (PCDC) and the Stand Up To Cancer-Lustgarten Foundation Pancreatic Cancer Interception Dream Team. She is a founding member of the World Pancreatic Cancer Coalition and is also on the board of the American Pancreatic Foundation and the Board of Associate Editors for Pancreas Journal.

Kenner is a founding partner of Neuropsychological Assessment and Consultation Services LLP, which provides neuropsychological assessment services for children, adolescents and adults.

She earned her PhD from New York University Steinhardt School and completed pre- and postdoctoral fellowships at Mount Sinai Medical Center in New York City.

A past member of the NYU Steinhardt Dean's Council, she has received the school's Distinguished Alumna Achievement Award.

Kenner lives in New York City, where she serves on various boards, including the Weizmann Institute's Women in Philanthropy and Bard College Music Festival. Kenner's family, including Nick and Ashley Kenner, Kate and Sam Archibald, and her four grandchildren, also live in New York City.

Michael A.G. Korengold

Chair, Audit and Investment Committee, New York

Michael A.G. Korengold is a finance executive based in New York City. His commitment to fighting pancreatic cancer is rooted in the loss of his mother, Melanie Gainsley, to the disease in 1995.

Currently, Korengold is President and Chief Executive Officer of Enhanced Capital, a national asset management firm focused on lending to businesses throughout the United States. He serves on the firm's Investment Committees and Board of Directors. Prior to becoming president in 2003, Korengold was the company's Sr. Vice President and General Counsel. Earlier, he practiced law in Minneapolis and New Orleans, with an emphasis on corporate finance.

Korengold has lectured extensively on capital formation programs and has testified before numerous state legislatures and other governmental institutions on related issues. He has also served on the boards of numerous civic, community and charitable organizations and is currently a co-chairman of the Young Presidents' Organization, Gotham Chapter.

After receiving his bachelor's degree from Vassar College in 1986, Korengold graduated magna cum laude from the University of Minnesota Law School in 1993. There, he was a member of the Order of the Coif honor society and served as an editor of the Law Review.

Korengold lives in Bronxville, New York, with his wife, Jonalie, and his two children, Ben and Gainsley, who is named after his mother.

Jason Kuhn

Tampa, FL

Jason Kuhn was born and raised in Allentown, Penn., and for the past 25 years has been a serial entrepreneur. During this time, he has been involved in ventures in automotive retailing, insurance, technology, software and pet care.

In 2016, Kuhn led the negotiations on behalf of the 652 Volkswagen dealers against Volkswagen AG for committing diesel violations, that resulted in the largest settlement ever recorded against an automobile manufacturer in favor of its distribution network.

Kuhn, who began his career as an M&A tax consultant for KPMG in its New York City headquarters, has a degree in business administration from the Olin School of Business at Washington University in St. Louis, a law degree from Cardozo School of Law at Yeshiva University, and an LL.M. in Tax Law from the NYU School of Law.

He first joined the board of directors of the Pancreatic Cancer Action Network in 2003, shortly after his father was diagnosed with pancreatic cancer. He served for nine years and spent three-and-a-half of those years as chair before taking a short hiatus. He is delighted to rejoin the board for a second term.

In a private capacity, Kuhn and his wife, Courtney, support many philanthropic causes. They have four children and split their time between Chicago and Tampa, Fla.

Lisa Kulok

Portland, Ore.

Lisa Kulok joined the Pancreatic Cancer Action Network (PanCAN) board of directors in September 2019. Kulok brings more than 30 years of organizational and operational knowledge to the role.

Kulok joined Columbia Sportswear in February 2008 and has served as Senior Vice President of Global Supply Chain Operations since May 2015. Prior to Columbia, Kulok held various leadership positions at NIKE, Inc. for more than 20 years. During this time, she led numerous teams that developed and implemented planning and supply chain processes, systems and organizations that supported growth of the company's annual revenues from $1 billion to $18 billion.

Kulok became a passionate supporter of PanCAN after losing her mother, Carol, to pancreatic cancer in September 2016 following a two-and-a-half-year battle with the disease. Kulok is an active participant in PurpleStride Orange County, serving as Team Captain for Carol’s Purple Crusaders. The team has raised more than $50,000 for PanCAN since 2014.

She lives in Portland, Ore., with her wife Diana and their dog Gracie.

Terrence Meck

Provincetown, Mass.

Terrence Meck is co-founder and president of The Palette Fund, a private foundation dedicated to advancing social change in communities that are under-resourced and facing significant challenges. The Palette Fund honors the legacy of his late partner Rand Skolnick who lost his battle to pancreatic cancer in 2008. Since its inception, the foundation has granted more than $5 million to over 125 organizations throughout the United States and abroad.

Meck also serves as president of Intrinsic Capital, a small investment firm dedicated to providing seed-stage funding to socially progressive startups. He recently finished his term as president of Threshold Foundation, a community of individuals united by their commitment to create a just, joyful and generative world.

Meck currently holds positions on the board of directors of the Pancreatic Cancer Action Network, Movement Advancement Project, God's Love We Deliver and The Provincetown Commons. He received his BA from Princeton University and splits his time between New Orleans and Provincetown, Massachusetts.

Craig A. Rogerson

Columbus, OH

Craig Rogerson is Chairman, President and Chief Executive Officer at Hexion Inc. A father to three, Rogerson lost his first wife Carina to pancreatic cancer in 2009.

Rogerson joined Hexion in July 2017. Prior to joining Hexion, Rogerson served as Chairman, President and Chief Executive Officer of Chemtura Corporation, a position he held from December 2008 until April 21, 2017. Rogerson also served as President, Chief Executive Officer and Director of Hercules Incorporated from December 2003 until November 2008. Rogerson joined Hercules in 1979 and served in a number of management positions before leaving the company to serve as President and Chief Executive Officer of Wacker Silicones Corporation in 1997. In May 2000, Rogerson rejoined Hercules and was named President of its BetzDearborn Division in August 2000. Prior to being named CEO of Hercules in December 2003, Rogerson held a variety of senior management positions with the company, including president of the FiberVisions and Pinova Divisions, vice president of Global Procurement, and Chief Operating Officer.

Mr. Rogerson serves on the boards of directors of PPL, the Society of Chemical Industry, and the American Chemistry Council.

He holds a chemical engineering degree from Michigan State University, and serves on the advisory board of the Michigan State University Department of Chemical Engineering & Materials Science (MSU CHEMS).

Nancy Stagliano, Ph.D.

Santa Ynez, CA

Nancy Stagliano, Ph.D., is an accomplished serial biotechnology entrepreneur. Currently, Dr. Stagliano is Chief Executive Officer of Neuron23, a venture-backed company discovering and developing therapeutics for genetically driven neurodegenerative diseases such as Parkinson’s disease. In addition, Dr. Stagliano serves on numerous private company biotechnology boards, including Pandion Therapeutics.

Previously, as CEO, she successfully launched and/or exited three consecutive biotech companies: CytomX Therapeutics (CTMX), iPierian and, most recently, True North Therapeutics. As Chief Executive Officer and Co-founder of True North Therapeutics, Dr. Stagliano led the company to its recent acquisition by Bioverativ Inc., for a total deal value of up to $825 million. Under her leadership, True North discovered and developed a first-in-class monoclonal antibody in the classical complement pathway TNT009, which received breakthrough therapy designation from the U.S. Food & Drug Administration for the orphan indication, Cold Agglutinin Disease.

Previously, Dr. Stagliano was Chief Executive Officer of iPierian, Inc., which applied human iPSCs to model neurodegenerative diseases. The company and its lead antibody program against Tau for the treatment of progressive supranuclear palsy (PSP) and Alzheimer’s disease were acquired by Bristol-Myers Squibb in April of 2014 for a total deal value of $725 million; the antibody is currently in a Phase 2 trial in AD led by Biogen. From 2008–2010, Dr. Stagliano was the Chief Executive Officer and Co-founder of CytomX Therapeutics and a lead inventor on the CytomX Probody platform. Before moving to California, Dr. Stagliano worked in Cambridge, Mass., where she had an eight-year tenure at Millennium Pharmaceuticals.

Dr. Stagliano received her Bachelor of Science degree in electrical engineering and Master of Science degree in biomedical engineering from Drexel University in Philadelphia. She obtained her Doctor of Philosophy degree in neuroscience from the University of Miami, Miller School of Medicine, in Miami.

Emeritus Board of Directors

Cynthia Stroum
Founding Board Chair
Seattle, WA
Deborah Barbara
Baltimore, MD
Toni Dachis
Minneapolis, MN
Stephanie R. Davis
Sherman Oaks, CA
Tim Ennis
North Port, FL
Stevan R. Holmberg
Potomac, MD
Paula Kim
Green Cove Springs, FL
Peter Kovler
Washington, D.C. 
Terry Lierman
Chevy Chase, MD
Malissa Lischin
Brooklyn, NY
Laurie MacCaskill
Los Angeles, CA
Pamela Acosta Marquardt
Rancho Cucamonga, CA
Jai Pausch
Chesapeake, VA
Jeanne Weaver Ruesch
Chevy Chase, MD
Stuart Rickerson
Rancho Santa Fe, CA
Christian Riley
Ponte Vedra, FL
Philip S. Schein, MD
Stuart, FL
Judith Stein
Laguna Beach, CA
Randy Stein
Laguna Beach, CA
Michael Sweig
Chicago, IL
Rodney Van Johnson
Sherman Oaks, CA
Rick Weisheimer 
Columbus, OH
Created with Sketch.
bio image